Skip to search formSkip to main contentSkip to account menu

masitinib

Known as: 4-((4-methylpiperazin-1-yl)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide, masatinib 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (3)

AB 1010kinavet CA-1masivet
Inhibition of Cell ProliferationPositive Regulation of ApoptosisReceptor Tyrosine Kinase InhibitionSignal Transduction Inhibition

Broader (1)

Thiazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
LC–MS/MS method for the quantification of masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate
AbstractMasitinib (MST) is a selective tyrosine kinase inhibitor. Validated liquid chromatography tandem mass spectrometric… 
Review
2015
Review
2015
Masitinib for the treatment of mild to moderate Alzheimer’s disease
Alzheimer’s disease (AD) is a degenerative neurological disorder that is the most common cause of dementia and disability in… 
Review
2015
Review
2015
Novel agents for advanced pancreatic cancer
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways… 
2014
2014
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
Highly Cited
2012
Highly Cited
2012
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
BackgroundTreatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast… 
Highly Cited
2011
Highly Cited
2011
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
IntroductionNeuroinflammation is thought to be important in Alzheimer's disease pathogenesis. Mast cells are a key component of… 
Highly Cited
2010
Highly Cited
2010
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
OBJECTIVE To evaluate the effectiveness of masitinib for the treatment of nonresectable mast cell tumors (MCTs) in dogs at 12 and… 
Highly Cited
2010
Highly Cited
2010
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
PurposeTo evaluate the efficacy and safety of masitinib combined with gemcitabine in patients with advanced pancreatic cancer… 
Highly Cited
2009
Highly Cited
2009
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study
IntroductionSince current treatment options for patients suffering from active rheumatoid arthritis (RA) remain inadequate… 
Highly Cited
2008
Highly Cited
2008
Masitinib is safe and effective for the treatment of canine mast cell tumors.
BACKGROUND Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)